Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

Completed · Phase 1

Conditions studied: Multiple Myeloma

In brief

This is a Phase I, open-label, multi-dose trial to define the MTD and tolerability of a regimen including lenalidomide, dexamethasone, and intravenous SGN-40 in patients with relapsed multiple myeloma.

Key facts

Study ID

NCT00525447

Run by

Seagen Inc.

People needed

36

Starts

2007-08-01

Expected to finish

2010-02-01

Last updated by the study team

2014-10-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of multiple myeloma.
• Received at least one prior systemic therapy other than single-agent corticosteroids.
• Measurable disease of monoclonal protein greater than or equal to 0.5 gram/dL in plasma or 0.5 gram/24 hr urine collection, or greater than 10 mg/dL free light chain (FLC) in serum as determined by serum FLC assay and provided the serum FLC ratio is abnormal.

You may not qualify if…

• Received an allogenic stem cell transplant.
• Previous intolerance of lenalidomide or dexamethasone.
• Primary invasive malignancy (other than multiple myeloma) within the last 3 years.

Where it is running

• Rocky Mountain Cancer Center — Denver, Colorado, United States
• H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
• Nebraska Methodist Hospital — Omaha, Nebraska, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Weill Medical College of Cornell University — New York, New York, United States
• Avera Cancer Institute — Sioux Falls, South Dakota, United States
• Baylor University Medical Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.